BGM Group (BGM) vs Immunic (IMUX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Immunic (IMUX) has outperformed BGM Group (BGM) over the past year, gaining 1.9% versus a loss of 96.7%. Over five years, IMUX leads with a -91.9% price change compared with -98.3% for BGM. Immunic is the larger company by market cap ($111.0 million vs $108.6 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BGM | IMUX |
|---|---|---|
| Share price | $8.13 | $6.99 |
| Market cap | $108.57M | $111.01M |
| 1-day change | 0.00% | -5.41% |
| YTD return | -92.77% | +30.90% |
| 1-year return | -96.73% | +1.90% |
| 5-year return | -98.31% | -91.88% |
| EPS (TTM) | $-4.80 | $-3.53 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $37.92M | — |
| Revenue growth (YoY) | +51.09% | — |
| Net income (latest FY) | $-19.94M | $-97.17M |
| Gross margin | 16.64% | — |
| Operating margin | -33.18% | — |
| Net margin | -52.59% | — |
| 52-week high | $263.70 | $17.43 |
| 52-week low | $0.00 | $5.06 |
| Distance from 52-week high | -96.92% | -59.90% |
| Analyst consensus | — | strong_buy |
| Avg. price target upside | — | +508.73% |
| Average volume | 6.18K | 343.44K |
| Shares outstanding | 12.69M | 15.88M |
| Employees | — | 100 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IMUX has outperformed BGM by 98.6 percentage points over the past year.
About BGM Group
BGM stock →BGM Group Ltd., through its subsidiaries, operates as a pharmaceutical and chemical company in China. The company operates through Diversified Pharmaceutical and Allied Products; AI Solution; and Insurance Business segments.
Health Care · Biotechnology: Pharmaceutical Preparations
About Immunic
IMUX stock →Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical and phase 2 clinical development for patients with relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.
Health Care · Biotechnology: Pharmaceutical Preparations · 100 employees
BGM vs IMUX FAQ
Which is bigger, BGM Group or Immunic?
Immunic (IMUX) is larger, with a market capitalization of $111.01M compared with $108.57M for BGM Group (BGM).
Which stock has performed better over the past year, BGM or IMUX?
IMUX returned +1.90% over the past 12 months, compared with -96.73% for BGM (price return, excluding dividends). Past performance does not predict future results.
Are BGM Group and Immunic in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.